Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions express strong agreement with the findings, especially noting that high hematocrit levels (>52%) pose increased risks, as seen in phrases like 'danger' and 'must consider.' The tone is serious and clinical, often highlighting implications for patient safety and practice adjustments, which underscores the high interest and impact in the message.
Many posts acknowledge the study's findings and emphasize the increased risks associated with polycythemia during testosterone therapy.
Posts demonstrate high engagement with the topic, referencing specific risk factors and clinical implications.
Discussions include practical advice, referencing clinical management like dose reduction and phlebotomy, indicating active involvement.
The groups acknowledge that the study's insights could influence clinical practices and patient safety protocols, reflecting significant impact.
"Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events & Venous Thromboembolism in the 1st Year of Therapy" Full Journal: https://t.co/v4Ys6giDrj Authored by: @SirpiNackeeran, @ranjithramamd, & more https://t.co/4n71ljUzbZ
"Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy" Full Journal ➡️ https://t.co/cHFKywxXUX Authored by: @jesse_ory, @SirpiNackeeran, @ranjithramamd, & MORE
"Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the 1st Year of Therapy"
In the 1st yr of #TRT, secondary polycythemia appears to increase risk of major adverse CVE and VTE. #testosterone https://t.co/Fdrlg90ypk
A worthy read for any #testosterone -rx'ing clinician. Take home message: Polycythemia secondary to TRT in the 1st year of therapy can increase the risk of MACE/VTE in these pts. >52% Hct = danger Consider dose reduction +/- therapeutic phlebotomy https://t.co/u8jit0vwaP
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy | Journal of Urology https://t.co/oWkfvr7gle
This video discusses how testosterone therapy can cause secondary polycythemia, increasing the risk of serious cardiovascular events and blood clots. It explains how to manage elevated red blood cell counts during TRT…
This discussion covers the pros and cons of TRT, including potential risks like atrial fibrillation, kidney injury, and blood pressure changes, based on recent studies. It explores different administration methods and…
If you’re on TRT or considering it, do it under the guidance of an experienced provider! They can monitor for adverse effects and adjust treatment if needed. Link to study: https://t.co/g2DAjZa3bQ
RT @JonBeilan: A worthy read for any #testosterone -rx'ing clinician. Take home message: Polycythemia secondary to TRT in the 1st year of t…
A worthy read for any #testosterone -rx'ing clinician. Take home message: Polycythemia secondary to TRT in the 1st year of therapy can increase the risk of MACE/VTE in these pts. >52% Hct = danger Consider dose reduction +/- therapeutic phlebotomy https://t.co/u8jit0vwaP
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy | Journal of Urology - MashupMD https://t.co/CvFdvMNlvS
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venou…
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venou…
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venou…
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venou…
"Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the 1st Year of Therapy"
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy | Journal of Urology https://t.co/ONM2gQ0eUP
@Bloodman @aoglasser @BobbieJeanSwei1 Putting this one here too. I love Twitter learning. #medtwitter https://t.co/empcOvmgce
@Bloodman @aoglasser @BobbieJeanSwei1 Just found this too-chart came to me today so THANK YOU for your input on this. Now for proper timing of holding preop testosterone - harder as pts don't want to stop, but DVT risk (mostly total joint patients) must be regarded with proper consideration. https://t.co/empcOvmgce
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events & Venous…
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events & Venous…
https://t.co/YTFKldAk1Y
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events & Venous…
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events & Venous…
RT @JUrology: "Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events & Venous…
"Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events & Venous Thromboembolism in the 1st Year of Therapy" Full Journal: https://t.co/v4Ys6giDrj Authored by: @SirpiNackeeran, @ranjithramamd, & more https://t.co/4n71ljUzbZ
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy | Journal of Urology - MashupMD https://t.co/hcsN3S4fcm
"Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy" Full Journal ➡️ https://t.co/cHFKywxXUX Authored by: @jesse_ory, @SirpiNackeeran, @ranjithramamd, & MORE
In the 1st yr of #TRT, secondary polycythemia appears to increase risk of major adverse CVE and VTE. #testosterone https://t.co/Fdrlg90ypk
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy | Journal of Urology https://t.co/oWkfvr7gle
... 10.1097/JU.0000000000002437). Et même dans ce cas, l'étude n'a montré aucun risque accru d'événements cardiovasculaires majeurs et de ...
... 10.1097/JU.0000000000002437 Authored by: Jesse Ory, Sirpi Nackeeran, Navin C. Balaji, Joshua M. Hare, and Ranjith Ramasamy | The Journal of ...
doi:10.1097/JU.0000000000002437. Share this article. facebook share Share on Facebook · twitter share Share on Twitter · linkedin share Share on ...
JU
S
JB
GE
JJ
KC
SM
SM
JO
AA
JM
MH
CD
KA
EH
LD